338 related articles for article (PubMed ID: 29594970)
1. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients.
Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS
Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970
[TBL] [Abstract][Full Text] [Related]
2. Combined Immunosuppression Impairs Immunogenicity to Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease.
Dezfoli S; Horton HA; Thepyasuwan N; Berel D; Targan SR; Vasiliauskas EA; Dubinsky M; Shih DQ; Kaur M; McGovern DP; Ippoliti A; Feldman EJ; Melmed GY
Inflamm Bowel Dis; 2015 Aug; 21(8):1754-60. PubMed ID: 25985242
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
6. Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
Nicácio AAMF; Peracchi OAB; Yamada J; Fraga MM; Vitalle MS; de Moraes-Pinto MI; Terreri MT
Vaccine; 2021 Feb; 39(7):1165-1172. PubMed ID: 33478788
[TBL] [Abstract][Full Text] [Related]
7. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
Embree J; Law B; Voloshen T; Tomovici A
Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease.
Caldera F; Misch EA; Saha S; Wald A; Zhang Y; Hubers J; Megna B; Ley D; Reichelderfer M; Hayney MS
Dig Dis Sci; 2019 Jan; 64(1):189-195. PubMed ID: 30317494
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
11. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
[TBL] [Abstract][Full Text] [Related]
13. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
15. Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Peracchi OA; Nicácio AAM; Yamada J; Len CA; Moraes-Pinto MI; Terreri MT
Lupus; 2021 Feb; 30(2):299-306. PubMed ID: 33197362
[TBL] [Abstract][Full Text] [Related]
16. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.
Carlsson RM; Gustafsson L; Hallander HO; Ljungman M; Olin P; Gothefors L; Nilsson L; Netterlid E
Vaccine; 2015 Jul; 33(31):3717-25. PubMed ID: 26057135
[TBL] [Abstract][Full Text] [Related]
17. Immune responses in infants whose mothers received Tdap vaccine during pregnancy.
Hardy-Fairbanks AJ; Pan SJ; Decker MD; Johnson DR; Greenberg DP; Kirkland KB; Talbot EA; Bernstein HH
Pediatr Infect Dis J; 2013 Nov; 32(11):1257-60. PubMed ID: 23799518
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
Blatter M; Friedland LR; Weston WM; Li P; Howe B
Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose.
Halperin SA; McNeil S; Langley J; Blatter M; Dionne M; Embree J; Johnson R; Latiolais T; Meekison W; Noya F; Senders S; Zickler P; Johnson DR
Vaccine; 2011 Oct; 29(46):8459-65. PubMed ID: 21803091
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.
Wei SC; Tatti K; Cushing K; Rosen J; Brown K; Cassiday P; Clark T; Olans R; Pawloski L; Martin M; Tondella ML; Martin SW
Clin Infect Dis; 2010 Aug; 51(3):315-21. PubMed ID: 20578875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
